Expression of activated TrkA protein in melanocytic tumors: Relationship to cell profileration and clinical outcome

American Journal of Clinical Pathology

Volumn 122, Issue 3, 2004, Pages 412-420

  Flørenes, Vivi Ann ^a   Mælandsmo, Gunhild M ^a   Holm, Ruth ^a   Reich, Reuven ^b   Lazarovici, Philip ^b   Davidson, Ben ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Cell cycle; E cadherin; MAPK; p75NTR; Prognosis; catenin

Indexed keywords

BETA CATENIN; CYCLIN A; MITOGEN ACTIVATED PROTEIN KINASE 1; NERVE GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; TUMOR MARKER; UVOMORULIN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVATION; EVALUATION; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MELANOCYTIC NEVUS; MELANOMA; METASTASIS; OUTCOMES RESEARCH; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN LOCALIZATION; SURVIVAL RATE; TISSUE SECTION; TUMOR BIOPSY; TUMOR VOLUME;

EID: 4344645086     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/CHFHEYAT44WWP7J3     Document Type: Article

References (42)

1. Barbacid M. Neurotrophic factors and their receptors. Curr Opin Cell Biol. 1995;7:148-155.
2. Kaplan DR, Miller FD. Signal transduction by the neurotrophin receptors. Curr Opin Cell Biol. 1997;9:213-224.
3. Patapoutian A, Reichardt LF. Trk receptors: mediators of neurotrophin action. Curr Opin Neurobiol. 2001;11:272-280.
4. Rudkin BB, Lazarovici P, Levi BZ, et al. Cell cycle-specific action of nerve growth factor in PC12 cells: differentiation without proliferation. EMBO J. 1989;8:3319-3325.
5. Yankner BA, Shooter EM. The biology and mechanism of action of nerve growth factor. Annu Rev Biochem. 1982;51:845-868.
6. Segal RA, Greenberg ME. Intracellular signaling pathways activated by neurotrophic factors. Annu Rev Neurosci. 1996;19:463-489.
7. Billon N, van Grunsven LA, Rudkin BB. The CDK inhibitor p21WAF1/Cip1 is induced through a p300-dependent mechanism during NGF-mediated neuronal differentiation of PC12 cells. Oncogene. 1996;13:2047-2054.
8. Gollapudi L, Neet KE. Different mechanisms for inhibition of cell proliferation via cell cycle proteins in PC12 cells by nerve growth factor and staurosporine. J Neurosci Res. 1997;49:461-474.
9. Brown A, Browes C, Mitchell M, et al. c-ab1 is involved in the association of p53 and trk A. Oncogene. 2000;19:3032-3040.
10. Montano X. p53 associates with trk tyrosine kinase. Oncogene. 1997;15:245-256.
11. Nakagawara A. Trk receptor tyrosine kinases: a bridge between cancer and neural development. Cancer Lett. 2001;169:107-114.
12. McGregor LM, McCune BK, Graff JR, et al. Roles of trk family neurotrophin receptors in medullary thyroid carcinoma development and progression. Proc Natl Acad Sci U S A. 1999;96:4540-4545.
13. Nakagawara A, Arima M, Azar CG, et al. Inverse relationship between trk expression and N-myc amplification in human neuroblastomas. Cancer Res. 1992;52:1364-1368.
14. Suzuki T, Bogenmann E, Shimada H, et al. Lack of high-affinity nerve growth factor receptors in aggressive neuroblastomas. J Natl Cancer Inst. 1993;85:377-384.
15. Descamps S, Pawlowski V, Revillion F, et al. Expression of nerve growth factor receptors and their prognostic value in human breast cancer. Cancer Res. 2001;61:4337-4340.
16. Zhu ZW, Friess H, Wang L, et al. Down-regulation of nerve growth factor in poorly differentiated and advanced human esophageal cancer. Anticancer Res. 2000;20:125-132.
17. Davidson B, Reich R, Lazarovizi P, et al. Expression and activation of the nerve growth factor receptor TrkA in serous ovarian carcinoma. Clin Cancer Res. 2003;9:2248-2259.
18. Cantarella G, Lempereur L, Presta M, et al. Nerve growth factor-endothelial cell interaction leads to angiogenesis in vitro and in vivo. FASEB J. 2002;16:1307-1309.
19. Roux PP, Bhakar AL, Kennedy TE, et al. The p75 neurotrophin receptor activates Akt (protein kinase B) through a phosphatidylinositol 3-kinase-dependent pathway. J Biol Chem. 2001;276:23097-23104.
20. Koh HK. Cutaneous melanoma. N Engl J Med. 1991;325:171-182.
21. Herrmann JL, Menter DG, Hamada J, et al. Mediation of NGF-stimulated extracellular matrix invasion by the human melanoma low-affinity p75 neurotrophin receptor: melanoma p75 functions independently of trkA. Mol Biol Cell. 1993;4:1205-1216.
22. Marchetti D, Menter D, Jin L, et al. Nerve growth factor effects on human and mouse melanoma cell invasion and heparanase production. Int J Cancer. 1993;55:692-699.
23. Marchetti D, Nicolson GL. Neurotrophin stimulation of human melanoma cell invasion: selected enhancement of heparanase activity and heparanase degradation of specific heparan sulfate subpopulations. Adv Enzyme Regul. 1997;37:111-134.
24. Nicolson GL, Nakajima M, Herrmann JL, et al. Malignant melanoma metastasis to brain: role of degradative enzymes and responses to paracrine growth factors. J Neurooncol. 1994;18:139-149.
25. Walch ET, Albino AP, Marchetti D. Correlation of over-expression of the low-affinity p75 neurotrophin receptor with augmented invasion and heparanase production in human malignant melanoma cells. Int J Cancer. 1999;82:112-120.
26. Easty DJ, Herlyn M, Bennett DC. Abnormal protein tyrosine kinase gene expression during melanoma progression and metastasis. Int J Cancer. 1995;60:129-136.
27. Innominato PF, Libbrecht L, van den Oord JJ. Expression of neurotrophins and their receptors in pigment cell lesions of the skin. J Pathol. 2001;194:95-100.
28. Hochman J, Park SS, Lazarovici P, et al. Monoclonal antibodies to immunogenic lymphoma cell variants displaying impaired neoplastic properties: characterization and applications. J Natl Cancer Inst. 1990;82:1821-1826.
29. Davidson B, Lazarovici P, Ezersky A, et al. Expression levels of the nerve growth factor receptors TrkA and p75 in effusions and solid tumors of serous ovarian carcinoma patients. Clin Cancer Res. 2001;7:3457-3464.
30. Flørenes VA, Mælandsmo GM, Kerbel RS, et al. Protein expression of the cell-cycle inhibitor p27Kip1 in malignant melanoma: inverse correlation with disease-free survival. Am J Pathol. 1998;153:305-312.
31. Mælandsmo GM, Holm R, Fodstad O, et al. Cyclin kinase inhibitor p21WAF1/CIP1 in malignant melanoma: reduced expression in metastatic lesions. Am J Pathol. 1996;149:1813-1822.
32. Flørenes VA, Mælandsmo GM, Faye R, et al. Cyclin A expression in superficial spreading malignant melanomas correlates with clinical outcome. J Pathol. 2001;195:530-536.
33. Flørenes VA, Faye RS, Mælandsmo GM, et al. Levels of cyclin D1 and D3 in malignant melanoma: deregulated cyclin D3 expression is associated with poor clinical outcome in superficial melanoma. Clin Cancer Res. 2000;6:3614-3620.
34. Jorgensen K, Holm R, Maelandsmo GM, et al. Expression of activated extracellular signal-regulated kinases 1/2 in malignant melanomas: relationship with clinical outcome. Clin Cancer Res. 2003;9:5325-5331.
35. Morin PJ. β-catenin signaling and cancer. Bioessays. 1999;21:1021-1030.
36. Mutoh T, Hamano T, Tokuda A, et al. Unglycosylated Trk protein does not co-localize nor associate with ganglioside GM 1 in stable clone of PC 12 cells overexpressing Trk (PCtrk cells). Glycoconij J. 2000;17:233-237.
37. Watson FL, Porcionatto MA, Bhattacharyya A, et al. TrkA glycosylation regulates receptor localization and activity. J Neurobiol. 1999;39:323-336.
38. Urdiates JL, Becker E, Andrieu M, et al. Cell cycle phase-specific surface expression of nerve growth factor receptors TrkA and p75(NTR). J Neurosci. 1998;18:6767-6775.
39. 1 phase cell cycle machinery. Bioessays. 2000;22:818-826.
40. Klesse LJ, Meyers KA, Marshall CJ, et al. Nerve growth factor induces survival and differentiation through two distinct signaling cascades in PC12 cells. Oncogene. 1999;18:2055-2068.
41. Ozawa M, Baribault H, Kemler R. The cytoplasmic domain of the cell adhesion molecule uvomorulin associates with three independent proteins structurally related in different species. EMBO J. 1989;8:1711-1717.
42. Mælandsmo GM, Holm R, Nesland JM, et al. Reduced β-catenin expression in the cytoplasm of advanced stage superficial spreading melanoma. Clin Cancer Res. 2003;9:3383-3388.